azacitidine has been researched along with abt-199 in 161 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 16 (9.94) | 24.3611 |
| 2020's | 145 (90.06) | 2.80 |
| Authors | Studies |
|---|---|
| Ahmann, G; Azorsa, DO; Bogenberger, JM; Braggio, E; Camoriano, J; Cardone, M; Choudhary, A; Chow, D; Coombes, KR; Fauble, V; Gonzales, IM; Kornblau, SM; Lena, R; Mantei, J; Mesa, RA; Pierceall, WE; Qiu, YH; Shi, CX; Stewart, AK; Tibes, R; Tiedemann, RE; Valdez, R; Yin, H | 1 |
| Bogenberger, JM; Delman, D; Fauble, V; Hansen, N; Mesa, RA; Tibes, R; Valdez, R | 1 |
| Müller-Tidow, C; Schlenk, RF | 1 |
| Bohl, SR; Bullinger, L; Rücker, FG | 1 |
| Konopleva, M; Letai, A | 1 |
| Das, M | 1 |
| Abbott, D; Culp-Hill, R; D'Alessandro, A; Gillen, AE; Gutman, JA; Hesselberth, JR; Jones, CL; Jordan, CT; Minhajuddin, M; Pei, S; Pollyea, DA; Purev, E; Riemondy, KA; Schatz, D; Smith, C; Stevens, BM; Winters, A | 1 |
| Adane, B; Culp-Hill, R; D'Alessandro, A; DeGregori, J; Jones, CL; Jordan, CT; Khan, N; Krug, A; Nemkov, T; Pei, S; Pollyea, DA; Reinhold, D; Reisz, JA; Smith, C; Stevens, BM; Ye, H | 1 |
| Aldoss, I; Marcucci, G; Mei, M; Pullarkat, V | 1 |
| Michaelis, LC | 1 |
| Nakada, D | 1 |
| Amit, O; Avivi, I; Bar-On, Y; Gurion, R; Raanani, P; Ram, R; Wolach, O; Zuckerman, T | 1 |
| Agarwal, S; Friedel, A; Gopalakrishnan, S; Hayslip, J; Kirschbrown, W; Menon, R; Mensing, S; Potluri, J; Salem, AH | 1 |
| Al Malki, MM; Aldoss, I; Ali, H; Aribi, A; Forman, SJ; Khaled, S; Marcucci, G; Mei, M; Nakamura, R; O'Donnell, M; Pillai, R; Pullarkat, V; Salhotra, A; Sanchez, JF; Sandhu, K; Snyder, D; Stein, AS; Sun, W; Yang, D | 1 |
| Gattermann, N; Germing, U; Kaivers, J; Kobbe, G; Kündgen, A; Schroeder, T | 1 |
| Abbott, D; Boggs, C; Chase, S; Ewalt, MD; Gutman, JA; Halsema, K; Jordan, CT; Kaiser, J; Lyle, L; Nakic, M; Pollyea, DA; Purev, E; Rana, V; Rosser, J; Schowinsky, JT; Schuster, S; Siegele, B; Smith, C; Stevens, BM; Tobin, J; Winters, AC | 1 |
| Contieri, B; Duarte, BKL; Lazarini, M | 1 |
| Bosi, A; Gianfaldoni, G; Grieco, P; Loscocco, GG; Palmieri, G; Piccini, M; Pilerci, S; Scappini, B | 1 |
| Boghaert, ER; Cojocari, D; Jin, S; Leverson, JD; Phillips, DC; Popovic, R; Purkal, JJ; Solomon, LR; Talaty, NN; Xiao, Y | 1 |
| Fan, C; Jiang, H; Jin, J; Li, J; Lou, Y; Lu, Y; Ma, Y; Mao, L; Shao, L | 1 |
| Carraway, HE; Chandhok, NS; Griffiths, EA; Prebet, T | 1 |
| Chen, Q; Li, M; Qiu, H; Sun, A; Wu, D; Wu, X; Zhang, J; Zhou, L | 1 |
| Azizi, A; Dutta, R; Ediriwickrema, A; Gotlib, J; Greenberg, P; Iberri, D; Majeti, R; Mannis, G; Medeiros, B; Patel, SA; Shomali, W; Zhang, T | 1 |
| Andrews, C; Maze, D; Murphy, T; Sibai, H | 1 |
| Caglioti, F; Gianfelici, V; Giugliano, E; Levato, L; Mannella, A; Molica, S; Russo, A | 1 |
| Naoe, T | 1 |
| Chen, TT; Cheng, FM; Lin, CC; Tien, JZ; Yeh, SP | 1 |
| Beutel, G; Eder, M; Gabdoulline, R; Gohring, G; Heuser, M; Koenecke, C; Krauter, J; Markel, D; Schlegelberger, B; Shahswar, R; Stadler, M; Thol, F; Trummer, A | 1 |
| Franklin, AK; Gore, L; Maloney, KW; Treece, AL; Winters, AC | 1 |
| DiNardo, CD; Döhner, H; Esteve, J; Fenaux, P; Garcia, JS; Hájek, R; Havelange, V; Hong, WJ; Illés, Á; Jang, JH; Jonas, BA; Koller, E; Konopleva, M; Lavie, D; Leber, B; Lemoli, RM; Letai, A; Pejsa, V; Porkka, K; Potluri, J; Pratz, KW; Pullarkat, V; Thirman, MJ; Turgut, M; Wang, J; Wei, AH; Yamamoto, K; Yeh, SP; Yoon, SS; Zhou, Y | 1 |
| Killock, D | 1 |
| Dutton, N; Fazal, S; Samhouri, Y; Tanvi, V; Ursu, S | 1 |
| Cheng, XH; Jiang, J; Jiang, M; Li, JH; Tang, MQ; Tian, FQ; Zhang, LS; Zhang, XC | 1 |
| Barrière, S; Gastaud, L | 1 |
| Arcaini, L; Boveri, E; Brociner, M; Castagnola, C; Merati, G; Nizzoli, ME; Roncoroni, E; Zappasodi, P | 1 |
| Ajib, S; Bornhäuser, M; Bug, G; Crysandt, M; Dressler, S; Haas, R; Hausmann, A; Heidenreich, D; Hirschbühl, K; Hoepting, M; Jost, E; Kaivers, J; Klein, S; Kobbe, G; Koldehoff, M; Kordelas, L; Kriege, O; Müller, LP; Rautenberg, C; Schaffrath, J; Schmid, C; Schroeder, T; Schuler, E; Wagner-Drouet, EM; Wolff, D | 1 |
| Chitikela, S; Kumar, L; Sahoo, RK | 1 |
| Lucijanic, M | 1 |
| Moore, JW; Pelcovits, A; Reagan, JL | 1 |
| DiNardo, CD; Pratz, KW; Wang, J | 1 |
| Bai, J; Lian, X; Pei, Z; Song, Q; Wang, H; Wang, J; Zhang, B | 1 |
| Gangat, N; Tefferi, A | 1 |
| Abbott, D; Amaya, M; Cherry, E; Gutman, JA; Jordan, CT; McMahon, C; Pollyea, DA; Schowinsky, J; Schwartz, M; Smith, C; Winters, A | 1 |
| Aggarwal, M; Dass, J; Dhawan, R; Kumar Vishwanathan, G; Kumar, P; Mahapatra, M; Senapati, J; Seth, T; Tyagi, S | 1 |
| Garcia-Horton, A; Gupta, V; Maze, D; McNamara, CJ; Murphy, T; Sibai, H | 1 |
| Huntington, SF; Patel, KK; Podoltsev, N; Prebet, T; Shallis, RM; Zeidan, AM | 1 |
| DiNardo, CD | 1 |
| Foster, MC; Green, SD; Richardson, DR; Zeidner, JF | 1 |
| Choi, I; Fukuhara, N; Honda, H; Hong, WJ; Nishimura, Y; Okubo, S; Potluri, J; Salem, AH; Taniguchi, S; Usuki, K; Yamauchi, T | 1 |
| Al-Kali, A; Alkhateeb, H; Begna, KH; Elliott, MA; Foran, JM; Gangat, N; Guglielmelli, P; Hanson, CA; Litzow, MR; Mannelli, F; Palmer, JM; Pardanani, A; Patnaik, MM; Szuber, N; Tefferi, A; Vannucchi, AM | 1 |
| Arrate, MP; Boghaert, ER; Cojocari, D; Gorska, A; Hogdal, LJ; Huska, JD; Phillips, DC; Purkal, JJ; Ramsey, HE; Savona, MR; Smith, BN; Xiao, Y | 1 |
| Azenkot, T; Jonas, BA; Moskoff, BN; Othman, TA; Tenold, ME | 1 |
| Agrawal, N; Ahmed, R; Bhurani, D; Choudhary, PS; Folbs, B; Kapoor, J; Khushoo, V; Mehta, P; Mirgh, S; Sharma, A; Tejwani, N | 1 |
| Chiesa, R; Mishra, AK; Mullanfiroze, K; Vora, A | 1 |
| Liu, SB; Qiao, M; Qiu, QC; Shen, XD; Wan, CL; Xue, SL; Yin, J; Zou, JY | 1 |
| Götze, KS; Hecker, JS; Pachzelt, L | 1 |
| Alvarado, Y; Daver, NG; DiNardo, CD; Kadia, TM; Kantarjian, HM; Konopleva, MY; Loghavi, S; Maiti, A; Ning, J; Ohanian, M; Qiao, W; Rausch, CR; Ravandi, F; Sasaki, K; Short, NJ; Takahashi, K; Venugopal, S; Yilmaz, M | 1 |
| Abdel-Wahab, O; Bhagat, TD; Boultwood, J; Dolatshad, H; Gavathiotis, E; Giricz, O; Gitego, N; Gordon-Mitchell, S; Inoue, D; Kazemi, M; Lee, J; Lopez, A; Maqbool, SB; Olea, R; Pellagatti, A; Pena, BR; Pradhan, K; Rahmani, NE; Ramachandra, N; Rao, K; Sahu, S; Shastri, A; Singh, S; Steidl, U; Sun, T; Tatwavedi, D; Tittrea, V; Verma, A; Zhang, J; Zhao, Y | 1 |
| Chai, X; Chen, Y; Deng, B; Fang, Q; Huang, S; Huang, Y; Kang, Q; Li, Y; Liu, M; Ma, D; Ni, M; Wang, J; Wen, S; Zhan, Y; Zhang, F; Zhang, Y; Zhao, M; Zhao, P | 1 |
| Abbott, D; Amaya, M; Cherry, EM; Gutman, JA; Inguva, A; Jordan, CT; McMahon, C; Minhajuddin, M; Pei, S; Pollyea, DA; Rosser, J; Sato, A; Schowinsky, J; Schwartz, M; Smith, C; Stevens, B; Winters, A | 1 |
| Amit, O; Avni, B; Pasvolsky, O; Raanani, P; Ram, R; Shargian, L; Shimoni, A; Shimony, S; Shochat, T; Wolach, O; Yerushalmi, R; Yeshurun, M | 1 |
| Abbott, D; Gutman, JA; Jordan, CT; McMahon, C; Pollyea, DA; Rabinovitch, R; Schwartz, M; Smith, CA; Winters, A | 1 |
| Bazarbachi, A | 1 |
| Makowka, P; Serve, H; Stolp, V; Stoschek, K | 1 |
| Al-Abri, M; Chan, SM; Chow, S; Hall, V; Rashedi, I; Tang, K; Tremblay-Lemay, R; Tsui, H | 1 |
| Asada, N; Asou, N; Choi, I; DiNardo, CD; Fukuhara, N; Honda, H; Ishizawa, K; Komatsu, N; Kurokawa, M; Matsumura, I; Miyamoto, T; Miyazaki, Y; Nakashima, Y; Okubo, S; Potluri, J; Pratz, KW; Shinagawa, A; Usuki, K; Yamamoto, K; Yamauchi, T; Yoshida, C; Zha, J; Zhou, Y | 1 |
| Boriskina, K; Cavelier, L; Hellström-Lindberg, E; Jädersten, M; Lindholm, C; Mielke, S; Tobiasson, M; Weström, S | 1 |
| Bao, XB; Hu, XH; Kong, JY; Kong, X; Li, MY; Qiu, HY; Song, BQ; Wu, DP; Wu, XX; Zhang, J; Zong, LH | 1 |
| Kasner, M; Wilde, L | 1 |
| Chyla, B; Dail, M; DiNardo, CD; Döhner, H; Fracchiolla, NS; Garcia, JS; Illes, A; Jang, JH; Jonas, BA; Ozcan, M; Potluri, J; Pratz, KW; Pullarkat, V; Recher, C; Schuh, AC; Thirman, MJ; Vorobyev, V; Yamamoto, K; Yeh, SP; Zhou, Y | 1 |
| Arellano, ML; Chyla, B; Dail, M; DiNardo, CD; Duan, Y; Fiedler, W; Kantarjian, HM; Konopleva, M; Lemoli, RM; Miller, CL; Pigneux, A; Pollyea, DA; Potluri, J; Rizzieri, DA; Shinagawa, A; Smith, BD | 1 |
| Chyla, B; Dail, M; DiNardo, CD; Duan, Y; Garcia, JS; Kantarjian, HM; Konopleva, M; Miller, CL; Potluri, J; Pratz, KW; Pullarkat, V; Recher, C; Thirman, MJ; Wei, AH | 1 |
| Argüello, RJ; Aroua, N; Avet-Loiseau, H; Boet, E; Bosc, C; Bousard, A; Cabon, F; Cognet, G; Farge, T; Fournié, JJ; Fovez, Q; Gadaud, N; Gotanègre, M; Jarrou, L; Joffre, C; Kaoma, T; Kaphan, E; Kluza, J; Larrue, C; Marine, JC; Mazzotti, C; Mouchel, PL; Nicot, N; Picard, M; Poillet-Perez, L; Polley, N; Rambow, F; Récher, C; Sabatier, M; Sahal, A; Saland, E; Sarry, JE; Stuani, L; Su, X; Tamburini, J; Tiong, IS; Tosolini, M; Vergez, F; Wang, Y; Wei, AH | 1 |
| Sato, S; Tamai, Y | 1 |
| Bassan, R; Candoni, A; De Bellis, E; Di Bona, E; Griguolo, D; Imbergamo, S; Lazzarotto, D; Leoncin, M; Liço, A; Lucchini, E; Mauro, E; Mosna, F; Palmieri, C; Poiani, M; Pravato, S; Stulle, M; Tanasi, I; Trentin, L; Zaja, F | 1 |
| Abe, H; Hirano, M; Ikegami, M; Inoue, N; Ishihara, Y; Maruyama, D; Mishima, Y; Nishimura, N; Onda, N; Shirouchi, Y; Takeuchi, K; Tamba, M | 1 |
| Arnaud, B; Garnache Ottou, F; Hutin, P; Ianotto, JC; Laribi, K; Le Calloch, R; Le Clech, L; Salmon, F | 1 |
| Al-Kali, A; Alkhateeb, H; Arana Yi, CY; Badar, T; Begna, KH; Foran, JM; Gangat, N; Hogan, W; Johnson, I; Litzow, MR; Mangaonkar, A; McCullough, K; Palmer, JM; Pardanani, A; Patnaik, MM; Shah, M; Sproat, L; Tefferi, A | 1 |
| Basak, GW; Drozd-Sokolowska, J; Feliksbrot-Bratosiewicz, M; Gierej, B; Mądry, K; Paszkowska-Kowalewska, M; Sankowski, B; Siewiorek, K; Sokołowski, J; Stefaniak, A; Stokłosa, T | 1 |
| Dai, H; Gao, X; Li, Y; Wang, W; Xue, Y; Yao, D | 1 |
| Barthélémy, A; Cheok, MH; Gonzales, F; Guilmatre, A; Lapillonne, H; Leverger, G; Petit, A; Pottier, N | 1 |
| Boyadzhiev, H; Ganster, C; Haase, D; Hasenkamp, J; Jung, W; Koch, R; Maulhardt, M; Mazzeo, P; Schmidt, N; Shumilov, E; Wulf, G | 1 |
| Huang, XJ; Jiang, H; Liu, XH; Wu, Y | 1 |
| Alexander, L; Alvarado, Y; Andreeff, M; Borthakur, G; Burger, JA; Daver, N; Dinardo, CD; Estrov, Z; Garcia-Manero, G; Issa, GC; Jabbour, E; Kadia, TM; Konopleva, M; Ma, J; Macaron, W; Masarova, L; Miller, D; Montalban-Bravo, G; Naing, A; Ning, J; Pemmaraju, N; Pierce, S; Ravandi, F; Sasaki, K; Short, NJ; Takahashi, K | 1 |
| Perl, AE; Vyas, P | 1 |
| Arora, S; Bachiashvili, K; Bathini, S; Bhatia, R; Di Stasi, A; Diamond, B; Godby, K; Gupta, U; Jamy, O; Oliver, JD; Rangaraju, S; Salzman, D; Vachhani, P; Worth, S; Zainaldin, C | 1 |
| Babushok, DV; Bruno, XJ; Carroll, MP; Frey, NV; Gill, SI; Hexner, EO; Hwang, WT; Loren, AW; Luger, SM; Maillard, IP; Margolis, D; Martin, ME; Matthews, AH; McCurdy, SR; Paralkar, VR; Perl, AE; Porter, DL; Pratz, KW; Stadtmauer, EA | 1 |
| Chen, RR; Jin, J; Li, L; Mai, WY; Meng, HT; Qian, JJ; Sun, JN; Tong, HY; Wang, LL; Xie, WZ; Ye, XJ; Yu, WJ; Zhang, Y; Zhu, HH; Zhu, LX | 1 |
| Chai, X; Downs, L; Iantuono, E; Ma, E; Montez, M; Nie, X; Pratz, KW; Xie, J; Yin, L | 1 |
| Andreeff, M; Bhalla, KN; Borthakur, G; Daver, NG; DiNardo, CD; Ferrajoli, A; Garcia-Manero, G; Issa, GC; Jabbour, E; Jain, N; Kadia, TM; Kanagal-Shamanna, R; Kantarjian, HM; Konopleva, MY; Malla, R; Montalban-Bravo, G; Ohanian, M; Pemmaraju, N; Popat, UR; Quagliato, K; Rausch, CR; Ravandi, F; Reville, PK; Sasaki, K; Short, NJ; Takahashi, K; Wang, X | 1 |
| Betts, KA; Bui, CN; Chai, X; Choi, M; Kapustyan, T; LeBlanc, TW; Ma, E; Montez, M; Song, J; Yin, L | 1 |
| Borthakur, G; Chien, KS; Daver, N; DeLumpa, R; Desikan, SP; Jabbour, EJ; Jain, N; Kadia, TM; Konopleva, M; Kwari, M; Loghavi, S; Macaron, W; Maiti, A; Montalban-Bravo, G; Pemmaraju, N; Ravandi, F; Short, NJ | 1 |
| Ai, J; Arnall, J; Avalos, BR; Boselli, D; Chen, T; Chiad, Z; Chojecki, AL; Copelan, EA; Cruz, A; DiSogra, KY; Grunwald, MR; Karabinos, A; Knight, TG; Patel, R; Ragon, BK; Sanikommu, SR; Shah, NA; Symanowski, J; Verbyla, A | 1 |
| Addo, SN; Boyiadzis, M; Fathi, AT; Hoffman, DM; Ivanov, V; Kang, K; Mayer, J; Mendes, WL; Saini, L; Unal, A; Yeh, SP | 1 |
| Baldus, C; Besenbeck, B; Blank, MF; Bornhäuser, M; Bruch, PM; Dietrich, S; Fabre, M; Göllner, S; Gu, M; Heid, D; Herbst, SA; Janssen, M; Jeremias, I; Knoll, M; Kolb, C; Krijgsveld, J; Ludwig, AK; Müller-Tidow, C; Pabst, C; Platzbecker, U; Przybylla, A; Raffel, S; Renders, S; Rohde, C; Röllig, C; Sauer, T; Schlenk, RF; Schmidt, C; Serve, H; Stölzel, F; Trumpp, A; Vassiliou, G; Vick, B; Vierbaum, L; Waclawiczek, A; Weidenauer, K | 1 |
| Beke, KE; Bryant, AL; Coombs, LA; Deal, AM; Foster, MC; Heiling, HM; Jensen, CE; Richardson, DR | 1 |
| Abbott, D; Bosma, G; Gutman, JA; Jordan, C; Minhajuddin, M; Pollyea, DA; Winters, AC | 1 |
| Al Jammal, M; Al-Juhaishi, T; Al-Kindi, SG; Arora, S; Badhwar, A; Chahine, N; Chami, T; Hajjari, J; Heisler, AC; Hoit, BD; Janus, SE; Mously, H | 1 |
| Babu, S; Chyla, B; Dail, M; DiNardo, CD; Jonas, BA; Pollyea, DA; Potluri, J; Pratz, KW; Pullarkat, V; Recher, C; Schuh, AC; Sun, Y; Wei, AH | 1 |
| DiNardo, C; Duan, Y; Fracchiolla, N; Ishizawa, K; Jang, JH; Jin, J; Jonas, BA; Kantarjian, H; Konopleva, M; Kovacsovics, T; Montesinos, P; Ofran, Y; Potluri, J; Pratz, KW; Pristupa, A; Werner, M | 1 |
| Brackman, D; DiNardo, CD; Duan, Y; Jin, H; Jonas, BA; Kantarjian, H; Konopleva, M; Li, J; Mayer, J; Montez, M; Potluri, J; Pratz, KW; Selleslag, D; Stevens, D; Traina, F; Venditti, A; Werner, M; Yamamoto, K; Zha, J | 1 |
| Pleyer, L; Sekeres, MA | 1 |
| Alvarado, Y; Andreeff, M; Bazinet, A; Chien, K; Colla, S; Darbaniyan, F; Ganan-Gomez, I; Garcia-Manero, G; Huang, X; Jabbour, E; Kadia, T; Kanagal-Shamanna, R; Kantarjian, H; Masarova, L; McCue, D; Mirabella, B; Montalban-Bravo, G; Ohanian, M; Qiao, W; Ravandi, F; Short, N; Takahashi, K; Yilmaz, M | 1 |
| Fang, M; Hu, W; Jiang, H; Liu, X; Tang, B; Wang, A; Wang, D; Zhang, X; Zhu, X | 1 |
| Chishaki, R; Edahiro, T; Fujino, K; Fukushima, N; Ichinohe, T; Mino, T; Ureshino, H; Yoshida, T | 1 |
| Barankiewicz, J; Basak, GW; Biecek, P; Drozd-Sokołowska, J; Karakulska-Prystupiuk, E; Kobylińska, K; Mądry, K; Rytel, J; Salomon-Perzyński, A; Skwierawska, K; Stokłosa, T | 1 |
| Morita, Y | 1 |
| Amaya, M; Burke, E; Dale, J; Davis, S; Engel, K; Gasparetto, M; Gillen, A; Goodman, B; Gutman, J; Hull, M; Islam, N; Jordan, C; Larchick, L; McMahon, CM; Pei, S; Reuben, JS; Smith, C; Staggs, S; Stevens, B; Toninato, J; Weller, G; Zane, R | 1 |
| Green, SD; Zeidner, JF | 1 |
| Jia, Y; Li, C; Lin, D; Mi, Y; Wang, H; Wang, J; Wang, Z | 1 |
| Kobayashi, M; Kosugi, N; Suzaki, K; Yasu, T | 1 |
| Au, Y; Bui, CN; Chai, X; Guinan, K; Lachaine, J; Mathurin, K; Schuh, AC | 1 |
| Bajel, A; Borate, U; Brunner, AM; Cheng, WH; Filshie, R; Garcia, JS; Garcia-Manero, G; Harb, JG; Hoffman, D; Krishnadasan, R; Naqvi, K; Odenike, O; Pollyea, DA; Potluri, J; Roncolato, F; Watson, AM; Zeidan, AM; Zha, J; Zhou, Y | 1 |
| Gangat, N; Komrokji, RS; Tefferi, A | 1 |
| Anderson, D; Aya-Bonilla, C; Breese, EH; Brown, PA; Cheung, LC; Chiu, SK; Chua, GA; Cruickshank, MN; Faulk, KE; Ferrari, E; Ford, J; Guest, EM; Hesselman, MC; Hughes, AM; Jafari, R; Kees, UR; Kotecha, RS; Kuek, V; Kunold, E; Lock, RB; Loh, ML; Malinge, S; Oommen, J; Post, F; Singh, S | 1 |
| Blum, S; Bresser, H; Lübbert, M; Tsilimidos, G | 1 |
| Lu, Y; Pei, R; Yuan, J | 1 |
| Belhabri, A; Bertoli, S; Billotey, NC; Bulabois, C; Cartet, E; Dumas, PY; Fornecker, L; Giltat, A; Guepin, GR; Guerineau, E; Houyou, D; Hunault, M; Kaphan, E; Lachenal, F; Laloi, L; Laribi, K; Michallet, AS; Michallet, M; Michel, C; Morisset, S; Paul, F; Pigneux, A; Puisset, F; Récher, C; Rocher, C; Santagostino, A; Simand, C; Simonet, MB; Tabrizi, R; Villate, A | 1 |
| Jiang, L; Jin, J; Lang, W; Lu, C; Luo, Y; Ma, L; Mei, C; Ren, Y; Tong, H; Xu, G; Xu, W; Yang, H; Ye, L; Zhou, X; Zhu, H | 1 |
| Bang, SY; Cho, BS; Cho, SG; Eom, KS; Kim, HJ; Kim, YJ; Kwag, D; Lee, JH; Lee, JW; Lee, S; Lee, SE; Min, CK; Min, GJ; Park, S; Park, SS; Yoon, JH | 1 |
| Hennings, R; Kayser, S; Monecke, A; Ramdohr, F | 1 |
| Chang, XL; Guo, YX; Hu, RH; Hui, WH; Lan, XX; Su, L; Sun, WL; Zhang, Y; Zhao, H | 1 |
| Aiba, M; Miyagishima, T; Shigematsu, A; Suzuki, T | 1 |
| Basilico, CM; Bonuomo, V; Buzzatti, E; Candoni, A; Cattaneo, C; Cerqui, E; Dargenio, M; De Marchi, R; Del Principe, MI; Delia, M; Dragonetti, G; Fanin, R; Fracchiolla, N; Griguolo, D; Lazzarotto, D; Lessi, F; Luppi, M; Mellillo, L; Nadali, G; Olivieri, A; Pagano, L; Papayannidis, C; Pasciolla, C; Piccini, M; Piccioni, AL; Riva, M; Sarlo, C; Sartor, C; Sciumè, M; Spadea, A; Stulle, M; Tisi, MC | 1 |
| Kunisada, K; Matsuoka, A; Taoka, T; Yoshida, S | 1 |
| Stelmach, P; Trumpp, A | 1 |
| Bonifacio, G; Borate, U; Chen, C; Gaugler, L; Kiendrebeogo, Z; Pollyea, DA; Potluri, R; Prebet, T; Rotter, D; Strocchia, M; Vasconcelos, A; Zeidan, AM | 1 |
| Ambinder, AJ; Dalton, WB; DeZern, AE; Ghiaur, G; Gojo, I; Gondek, LP; Jain, T; Levis, MJ; Newman, M; Prince, GT; Sanber, K; Smith, BD; Tsai, HL; Webster, JA; Ye, K | 1 |
| Hu, Y; Huang, P; Li, J; Liu, C; Liu, H; Liu, Q; Wang, Y; Wu, L; Yang, Z; Zheng, Y | 1 |
| Matsuda, K; Sugimoto, K; Yoshida, T | 1 |
| Aribi, A; Ball, B; Marcucci, G; Pullarkat, V; Salhotra, A; Stein, A | 1 |
| Fukuda-Kurahashi, Y; Hoshiko, T; Kamachi, K; Kawasoe, K; Kimura, S; Kurahashi, Y; Ureshino, H; Watanabe, T; Yamamoto, Y; Yoshida-Sakai, N | 1 |
| Al-Kali, A; Alkhateeb, HB; Begna, KH; Gangat, N; Hogan, W; Ilyas, R; Johnson, IM; Litzow, MR; Mangaonkar, A; McCullough, K; Pardanani, A; Patnaik, MM; Shah, M; Tefferi, A | 1 |
| Chen, H; DiNardo, KW; LeBlanc, TW | 1 |
| Betz, B; Donato, E; Grabowski, S; Gryzik, S; Heuser, M; Hundemer, M; Janssen, M; Karpova, D; Leppä, AM; Müller-Tidow, C; Pabst, C; Raffel, S; Renders, S; Reyneri, C; Röllig, C; Sauer, T; Schlenk, RF; Shahswar, R; Stumpf, K; Thiel, V; Trumpp, A; Unglaub, JM; Vierbaum, L; Waclawiczek, A | 1 |
| Beechinor, R; Guglielmo, J; Jonas, BA; Kneen, R; Krackeler, ML; Leija, C; Moskoff, B; Pervitsky, V; Sawicky, D | 1 |
| Altman, JK; Attar, EC; Fathi, AT; Garcia-Manero, G; Goldberg, AD; Hickman, DK; Kanagal-Shamanna, R; Kantarjian, H; Komrokji, R; Lancet, J; Miller, C; Odenike, O; Roboz, GJ; Sallman, DA; Sweet, K; Wennborg, A; Winer, ES | 1 |
| Gando, Y; Yasu, T | 1 |
| Hu, C; Jin, J; Liu, Y; Lv, Z; Mao, L; Meng, H; Wang, J; You, L; Zhou, Y; Zhu, L | 1 |
| Akazawa, Y; Fujita, J; Fukushima, K; Hino, A; Hosen, N; Kawamura, A; Kusakabe, S; Matsui, T; Miyagawa, S; Sakata, Y; Sudo, T; Ueda, T; Yokota, T | 1 |
| Chung, P; Diorio, C; Niswander, LM; Tasian, SK | 1 |
| Abbott, D; Amaya, M; Brecl, C; Dell-Martin, J; Falco, A; Gutman, JA; Ho, P; Jordan, CT; Kent, A; McMahon, C; Minhajuddin, M; O'Brien, K; Ondracek, O; Pei, S; Pollyea, DA; Schowinsky, J; Smith, C; Sohalski, C; Stevens, B; Taylor, E; Tobin, J; Winters, A; Zhou, K | 1 |
| Borthakur, G; Bose, P; Daver, NG; DiNardo, CD; Duose, DY; Garcia, JS; Garcia-Manero, G; Jabbour, EJ; Jakobsen, NA; Kadia, TM; Kantarjian, H; Kim, YJ; Konopleva, M; Lachowiez, CA; Loghavi, S; Luskin, MR; Masarova, L; Ravandi, F; Short, NJ; Takahashi, K; Tanaka, T; Tidwell, RSS; Tippett, GD; Turkalj, S; Uryu, H; Vyas, P; Zeng, Z | 1 |
| Ge, L; Jiang, L; Jin, F; Li, J; Qian, W; Tian, W; Xia, L; Yang, M; Zhao, Y | 1 |
| Bobin, A; Cayssials E, E; Chomel, JC; Desmier, D; Gallego-Hernanz, P; Gardeney, H; Maillard, N; Moya, N; Systchenko, T; Torregrosa, J; Vonfeld, M | 1 |
| Aoyama, K; Fukuyama, T; Maehiro, Y; Mouri, F; Nagafuji, K; Nakamura, T; Oya, S; Ozawa, H; Takaki, Y; Yamaguchi, M; Yamasaki, Y | 1 |
| Anemona, L; Ardu, NR; Cesini, L; de Fabritiis, P; Fratoni, S; Giovannini, M; Mazzone, C; Niscola, P; Ottone, T; Voso, MT | 1 |
| Aladağ Karakulak, E; Büyükaşık, Y; Çınar, OE; Demiroğlu, H; Göker, H; Malkan, ÜY | 1 |
| Ma, J; Morimoto, K; Parekh, C; Pulsipher, MA | 1 |
| Imada, K; Ishikawa, T; Kanda, J; Kondo, T; Mizutani, Y; Muranushi, H; Naka, R; Nakabo, Y; Nannya, Y; Nishikubo, M; Ogawa, S; Oka, T; Okada, S; Ueda, Y; Wada, F; Watanabe, M; Yamamoto, S | 1 |
| Blank, MF; Corbacioglu, A; Göllner, S; Heid, D; Janssen, M; Krijgsveld, J; Lotze, M; Müller-Tidow, C; Pabst, C; Pauli, C; Raffel, S; Renders, S; Rohde, C; Sauer, T; Schmidt, C; Trumpp, A; Vierbaum, L; Waclawiczek, A; Weidenauer, K | 1 |
| Fan, J; Wen, X; Yu, J; Zheng, H; Zhu, S | 1 |
| Fujii, F; Kakinoki, Y; Matsuoka, S; Nojima, S | 1 |
| Bao, X; Carter, JL; Edwards, H; Ge, Y; Howard, M; Hüttemann, M; Li, J; Qiao, X; Su, Y; Taub, JW; Wang, G; Yang, J; Zhao, J | 1 |
| Alnimer, Y; Boron, J; Bouligny, IM; Doyel, M; Gor, J; Grant, S; Hang, Y; Ho, T; Maher, KR; Murray, G; Patel, T; Tran, V; Venn, C; Wages, NA; Zacholski, K | 1 |
| Andoh, A; Asai-Nishishita, A; Fujishiro, A; Iwasa, M; Kawahara, M; Kito, K; Minamiguchi, H; Murata, M; Nishimura, R; Tatsumi, G | 1 |
| Fujita, J; Hirose, Y; Kamimura, R; Kiyohara, E; Nagate, Y; Nakaya, A; Nojima, S; Shibayama, H | 1 |
| Agarwal, A; Bottomly, D; Chang, BH; Dibb, CA; Druker, BJ; Eide, CA; Huang, A; Joshi, SK; Kaempf, A; Kurtz, SE; Lachowiez, CA; Long, N; McWeeney, SK; Minnier, J; Nechiporuk, T; Saultz, JN; Swords, RT; Taylor, A; Tyner, JW | 1 |
| Betts, KA; Bui, CN; Dua, A; Lachaine, J; Li, X; Pratz, K; Schuh, AC; Song, J; Suh, HS | 1 |
| Acharya, L; Dhakal, P; Loeffler, B; Mott, S; Ravindra, A; Sutamtewagul, G | 1 |
| Benedek, S; Bödör, C; Farkas, P; Gaál, L; Horváth, L; Masszi, A; Masszi, T; Nagy, Z; Ruff, E; Svorenj, S; Szita, VR; Szombath, G; Tóth, AD; Varga, G; Várkonyi, J; Wiedemann, Á | 1 |
21 review(s) available for azacitidine and abt-199
| Article | Year |
|---|---|
Epigenetic therapy: azacytidine and decitabine in acute myeloid leukemia.
Topics: Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Decitabine; Epigenesis, Genetic; Gene Expression Regulation, Leukemic; Humans; Leukemia, Myeloid, Acute; Sulfonamides | 2018 |
BCL-2 inhibition in AML: an unexpected bonus?
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Decitabine; Humans; Leukemia, Myeloid, Acute; Proto-Oncogene Proteins c-bcl-2; Sulfonamides | 2018 |
Hypomethylating agents in combination with venetoclax for acute myeloid leukemia: Update on clinical trial data and practical considerations for use.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials as Topic; Decitabine; Drug Administration Schedule; Drug Synergism; Humans; Leukemia, Myeloid, Acute; Practice Guidelines as Topic; Remission Induction; Sulfonamides; Survival Analysis; Treatment Outcome | 2019 |
Novel therapies in low- and high-risk myelodysplastic syndrome.
Topics: Activin Receptors, Type II; Anemia; Antineoplastic Agents; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Decitabine; Erythrocyte Transfusion; Hematinics; Humans; Immunoglobulin Fc Fragments; Iron Chelating Agents; Lenalidomide; Myelodysplastic Syndromes; Oligonucleotides; Prognosis; Recombinant Fusion Proteins; Risk Assessment; Stem Cell Transplantation; Sulfonamides; Thalidomide; Thrombopoietin; Transplantation, Homologous | 2019 |
Updates on DNA methylation modifiers in acute myeloid leukemia.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials as Topic; Decitabine; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; DNA, Neoplasm; Enzyme Inhibitors; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Meta-Analysis as Topic; Molecular Targeted Therapy; Multicenter Studies as Topic; Neoplasm Proteins; Sulfonamides; Treatment Outcome | 2020 |
Advances in non-intensive chemotherapy treatment options for adults diagnosed with acute myeloid leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Benzimidazoles; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Decitabine; Gemtuzumab; Glycine; Humans; Leukemia, Myeloid, Acute; Male; Molecular Targeted Therapy; Phenylurea Compounds; Precision Medicine; Pyridines; Recurrence; Remission Induction; Staurosporine; Sulfonamides | 2020 |
Combination treatment with CPX-351 and midostaurin in patients with secondary acute myeloid leukaemia that are FLT3 mutated: three cases and review of literature.
Topics: Aged; Allografts; Anemia, Refractory, with Excess of Blasts; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Breast Neoplasms; Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials, Phase III as Topic; Cytarabine; Daunorubicin; Fatal Outcome; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Liposomes; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm, Residual; Neoplasms, Radiation-Induced; Oncogene Proteins, Fusion; Peripheral Blood Stem Cell Transplantation; Point Mutation; Protein Kinase Inhibitors; Pyrazines; Remission Induction; Salvage Therapy; Staurosporine; Sulfonamides | 2020 |
＜Editors' Choice＞ How to improve outcomes of elderly patients with acute myeloid leukemia: era of excitement.
Topics: Aged; Aged, 80 and over; Aminopyridines; Aniline Compounds; Antineoplastic Agents; Arsenic Trioxide; Azacitidine; Benzimidazoles; Bridged Bicyclo Compounds, Heterocyclic; Decitabine; fms-Like Tyrosine Kinase 3; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Molecular Targeted Therapy; Phenylurea Compounds; Precision Medicine; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Smoothened Receptor; Staurosporine; Sulfonamides; Survival Rate; Tretinoin; Triazines | 2020 |
Tagraxofusp followed by combined azacitidine and venetoclax in blastic plasmacytoid dendritic cell neoplasm: A case report and literature review.
Topics: Acute Disease; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Dendritic Cells; Hematologic Neoplasms; Humans; Male; Recombinant Fusion Proteins; Skin Neoplasms; Sulfonamides | 2021 |
[Venetoclax combined with azacitidine in the treatment of elderly patients with acute myeloid leukemia or myeloid sarcoma: Three cases reports and literature review].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Myeloid, Acute; Sarcoma, Myeloid; Sulfonamides | 2020 |
Venetoclax-based chemotherapy in acute and chronic myeloid neoplasms: literature survey and practice points.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials, Phase III as Topic; Cytarabine; Decitabine; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Randomized Controlled Trials as Topic; Sulfonamides | 2020 |
Secondary AML Emerging After Therapy with Hypomethylating Agents: Outcomes, Prognostic Factors, and Treatment Options.
Topics: Animals; Antineoplastic Agents; Azacitidine; Benzimidazoles; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Daunorubicin; Gemtuzumab; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Molecular Targeted Therapy; Phenylurea Compounds; Prognosis; Sulfonamides | 2021 |
An evaluation of venetoclax in combination with azacitidine, decitabine, or low-dose cytarabine as therapy for acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Decitabine; Humans; Leukemia, Myeloid, Acute; Sulfonamides | 2021 |
Costs per patient achieving remission with venetoclax-based combinations in newly diagnosed patients with acute myeloid leukemia ineligible for intensive induction chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Decitabine; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Network Meta-Analysis; Quality of Life; Sulfonamides | 2022 |
Design of the VIALE-M phase III trial of venetoclax and oral azacitidine maintenance therapy in acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Cell Division; Clinical Trials, Phase III as Topic; Humans; Leukemia, Myeloid, Acute; Randomized Controlled Trials as Topic; Sulfonamides | 2022 |
Reported Pericardial Toxicities Associated with Acute Myelogenous Leukemia Treatments: A Pharmacovigilance Analysis of the FDA Adverse Reporting Database.
Topics: Adolescent; Adult; Aminopyridines; Anthracyclines; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Cladribine; Cytarabine; Decitabine; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Pericarditis; Pharmacovigilance; Sulfonamides; Triazines; United States; United States Food and Drug Administration | 2022 |
[Treatment stratification by fitness for chemotherapy in acute myeloid leukemia].
Topics: Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Sulfonamides; United States | 2022 |
Role of Bcl-2 inhibition in myelodysplastic syndromes.
Topics: Aged; Azacitidine; Hematologic Neoplasms; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Proto-Oncogene Proteins c-bcl-2 | 2023 |
Leukemic stem cells and therapy resistance in acute myeloid leukemia.
Topics: Azacitidine; Humans; Leukemia, Myeloid, Acute; Neoplastic Stem Cells; Sulfonamides | 2023 |
Venetoclax and Azacitidine in the Treatment of
Topics: Azacitidine; Fanconi Anemia; Humans; Leukemia; Nuclear Proteins | 2023 |
Comparative Efficacy of Venetoclax-Based Combination Therapies and Other Therapies in Treatment-Naive Patients With Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy: A Network Meta-Analysis.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bayes Theorem; Cytarabine; Humans; Leukemia, Myeloid, Acute; Network Meta-Analysis; Treatment Outcome | 2023 |
14 trial(s) available for azacitidine and abt-199
| Article | Year |
|---|---|
Single-center pediatric experience with venetoclax and azacitidine as treatment for myelodysplastic syndrome and acute myeloid leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Child; Child, Preschool; Female; Follow-Up Studies; Humans; Infant; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Prognosis; Retrospective Studies; Sulfonamides; Young Adult | 2020 |
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Double-Blind Method; Female; Follow-Up Studies; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Leukopenia; Male; Middle Aged; Pneumonia; Recurrence; Remission Induction; Sulfonamides; Thrombocytopenia | 2020 |
Venetoclax in combination with azacitidine in Japanese patients with acute myeloid leukaemia: phase 1 trial findings.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Female; Humans; Japan; Leukemia, Myeloid, Acute; Male; Remission Induction; Sulfonamides; Survival Analysis; Treatment Outcome | 2021 |
Venetoclax plus azacitidine in Japanese patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Humans; Japan; Leukemia, Myeloid, Acute; Sulfonamides | 2022 |
Measurable Residual Disease Response and Prognosis in Treatment-Naïve Acute Myeloid Leukemia With Venetoclax and Azacitidine.
Topics: Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Myeloid, Acute; Neoplasm, Residual; Prognosis; Remission Induction; Sulfonamides | 2022 |
A multi-arm phase Ib/II study designed for rapid, parallel evaluation of novel immunotherapy combinations in relapsed/refractory acute myeloid leukemia.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Cohort Studies; Gemtuzumab; Humans; Immunotherapy; Leukemia, Myeloid, Acute; Sulfonamides | 2022 |
Cost-Effectiveness Analysis of Venetoclax in Combination with Azacitidine Versus Azacitidine Monotherapy in Patients with Acute Myeloid Leukemia Who are Ineligible for Intensive Chemotherapy: From a US Third Party Payer Perspective.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Cost-Benefit Analysis; Humans; Insurance, Health, Reimbursement; Leukemia, Myeloid, Acute; Quality-Adjusted Life Years; Sulfonamides; United States | 2022 |
Phase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Cladribine; Cytarabine; Humans; Leukemia, Myeloid, Acute; Middle Aged | 2022 |
A Phase II Study of Azacitidine, Venetoclax, and Trametinib in Relapsed or Refractory Acute Myeloid Leukemia Harboring RAS Pathway-Activating Mutations.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Myeloid, Acute; Mitogen-Activated Protein Kinase Kinases; Mutation; Pyridones; Pyrimidinones; Sulfonamides | 2022 |
Azacitidine plus venetoclax in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: phase 1 results of a single-centre, dose-escalation, dose-expansion, phase 1-2 study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Female; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Male; Myelodysplastic Syndromes; Proto-Oncogene Proteins c-bcl-2; Sulfonamides | 2022 |
A phase 1b study of venetoclax and azacitidine combination in patients with relapsed or refractory myelodysplastic syndromes.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Female; Humans; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Neutropenia; Sulfonamides; Treatment Outcome | 2023 |
Eprenetapopt combined with venetoclax and azacitidine in TP53-mutated acute myeloid leukaemia: a phase 1, dose-finding and expansion study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Thrombocytopenia; Treatment Outcome; Tumor Suppressor Protein p53 | 2023 |
Higher-dose venetoclax with measurable residual disease-guided azacitidine discontinuation in newly diagnosed acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Myeloid, Acute; Neoplasm, Residual | 2023 |
A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Myeloid Malignancies.
Topics: Antineoplastic Agents; Azacitidine; Humans; Isocitrate Dehydrogenase; Neoplasm Recurrence, Local | 2023 |
126 other study(ies) available for azacitidine and abt-199
| Article | Year |
|---|---|
BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignancies.
Topics: Antimetabolites, Antineoplastic; Azacitidine; bcl-X Protein; Biphenyl Compounds; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Myeloid Cell Leukemia Sequence 1 Protein; Myeloproliferative Disorders; Nitrophenols; Piperazines; Proto-Oncogene Proteins c-bcl-2; RNA Interference; Sulfonamides | 2014 |
Ex vivo activity of BCL-2 family inhibitors ABT-199 and ABT-737 combined with 5-azacytidine in myeloid malignancies.
Topics: Antineoplastic Agents; Azacitidine; Biphenyl Compounds; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Humans; Leukemia, Myeloid; Nitrophenols; Piperazines; Proto-Oncogene Proteins c-bcl-2; Sulfonamides | 2015 |
A new option for remission induction in acute myeloid leukaemia.
Topics: Aged; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Decitabine; Humans; Leukemia, Myeloid, Acute; Remission Induction; Sulfonamides | 2018 |
Venetoclax with decitabine or azacitidine for AML.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials as Topic; Decitabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Multicenter Studies as Topic; Sulfonamides; Time Factors; Treatment Outcome | 2018 |
Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia.
Topics: Aged; Aged, 80 and over; Apoptosis; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Electron Transport Complex II; Energy Metabolism; Female; Humans; Ketoglutaric Acids; Leukemia, Myeloid, Acute; Male; Neoplastic Stem Cells; Oxidative Phosphorylation; Proto-Oncogene Proteins c-bcl-2; Succinate Dehydrogenase; Sulfonamides; Tricarboxylic Acids | 2018 |
Inhibition of Amino Acid Metabolism Selectively Targets Human Leukemia Stem Cells.
Topics: Amino Acids; Animals; Antineoplastic Agents; Azacitidine; Biological Transport; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Fatty Acids; Female; Glycolysis; Humans; Leukemia, Myeloid, Acute; Lipid Metabolism; Metabolome; Mice; Neoplastic Stem Cells; Oxidative Phosphorylation; Proto-Oncogene Proteins c-bcl-2; Sulfonamides | 2018 |
Venetoclax in AML: aiming for "just right".
Topics: Aged; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Decitabine; Humans; Leukemia, Myeloid, Acute; Sulfonamides | 2019 |
Venetolax with Azacitidine Drains Fuel from AML Stem Cells.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Energy Metabolism; Humans; Leukemia, Myeloid, Acute; Stem Cells; Sulfonamides | 2019 |
Venetoclax in patients with acute myeloid leukemia refractory to hypomethylating agents-a multicenter historical prospective study.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Chemotherapy-Induced Febrile Neutropenia; Decitabine; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prospective Studies; Remission Induction; Sulfonamides; Survival Analysis; Transplantation, Homologous | 2019 |
Optimizing venetoclax dose in combination with low intensive therapies in elderly patients with newly diagnosed acute myeloid leukemia: An exposure-response analysis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials, Phase I as Topic; Cytarabine; Decitabine; DNA Methylation; Dose-Response Relationship, Drug; Humans; Leukemia, Myeloid, Acute; Molecular Targeted Therapy; Remission Induction; Sulfonamides; Treatment Outcome | 2019 |
Association of leukemia genetics with response to venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allografts; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Combined Modality Therapy; Decitabine; Disease-Free Survival; DNA, Neoplasm; Female; Hematopoietic Stem Cell Transplantation; High-Throughput Nucleotide Sequencing; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Neoplasm Proteins; Remission Induction; Retrospective Studies; Risk Assessment; Sulfonamides; Treatment Outcome; Young Adult | 2019 |
Real-world experience of venetoclax with azacitidine for untreated patients with acute myeloid leukemia.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Female; Follow-Up Studies; Genetic Testing; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm, Residual; Prognosis; Remission Induction; Sulfonamides; Treatment Outcome | 2019 |
Quick complete response achievement with venetoclax and azacitidine in a case of relapsed disseminated blastic plasmacytoid dendritic cell neoplasm.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Dendritic Cells; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Skin Neoplasms; Sulfonamides; Treatment Outcome | 2020 |
5-Azacitidine Induces NOXA to Prime AML Cells for Venetoclax-Mediated Apoptosis.
Topics: Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Disease Models, Animal; DNA Methylation; Dose-Response Relationship, Drug; Drug Synergism; Gene Expression Regulation, Leukemic; Gene Knockdown Techniques; Humans; Leukemia, Myeloid, Acute; Mice; Proto-Oncogene Proteins c-bcl-2; Sulfonamides | 2020 |
Efficacy and predictive factors of venetoclax combined with azacitidine as salvage therapy in advanced acute myeloid leukemia patients: A multicenter retrospective study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Recurrence; Remission Induction; Retrospective Studies; Salvage Therapy; Sulfonamides; Survival Analysis; Treatment Outcome | 2020 |
Efficacy of venetoclax in combination with azacitidine followed by haploidentical transplantation in refractory acute myeloid leukaemia and mixed phenotype acute leukaemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Combined Modality Therapy; Drug Resistance, Neoplasm; Female; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Biphenotypic, Acute; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Nausea; Oncogene Proteins, Fusion; Sulfonamides; Transplantation, Haploidentical; Treatment Outcome; Vomiting | 2020 |
Venetoclax and hypomethylating agent therapy in high risk myelodysplastic syndromes: a retrospective evaluation of a real-world experience.
Topics: Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Decitabine; Humans; Myelodysplastic Syndromes; Retrospective Studies; Sulfonamides; Treatment Outcome | 2020 |
Sustained Complete Remission with Incomplete Hematologic Recovery (CRi) in a Patient with Relapsed AML and Concurrent BCR-ABL1 and CBFB Rearrangement Treated with a Combination of Venetoclax and 5-Azacytidine.
Topics: Antineoplastic Agents; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Fusion Proteins, bcr-abl; Hematologic Diseases; Humans; Karyotype; Leukemia, Myeloid, Acute; Male; Middle Aged; Oncogene Proteins, Fusion; Remission Induction; Sulfonamides | 2020 |
Venetoclax plus cytochrome P450 inhibitors without ramp-up strategy led to low risk of tumor lysis syndrome in acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Child; Creatinine; Cytochrome P-450 Enzyme Inhibitors; Drug Administration Schedule; Drug Synergism; Female; Humans; Hyperuricemia; Leukemia, Myeloid, Acute; Male; Middle Aged; Retrospective Studies; Sulfonamides; Triazoles; Tumor Lysis Syndrome; Urate Oxidase; Uric Acid; Young Adult | 2020 |
Risk of tumor lysis syndrome in patients with acute myeloid leukemia treated with venetoclax-containing regimens without dose ramp-up.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Decitabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Risk Factors; Sulfonamides; Tumor Lysis Syndrome | 2021 |
Venetoclax in AML: efficacy confirmed.
Topics: Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Myeloid, Acute; Sulfonamides | 2020 |
[European approvals: Glasdegib for Acute myeloid leukemia].
Topics: Antineoplastic Agents; Azacitidine; Benzimidazoles; Bridged Bicyclo Compounds, Heterocyclic; Drug Approval; Europe; Gemtuzumab; Hedgehog Proteins; Humans; Leukemia, Myeloid, Acute; Phenylurea Compounds; Randomized Controlled Trials as Topic; Sulfonamides | 2020 |
Venetoclax and azacytidine combination is an effective bridge to transplant strategy in relapsed/refractory acute myeloid leukemia patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Sulfonamides | 2021 |
Treatment of myeloid malignancies relapsing after allogeneic hematopoietic stem cell transplantation with venetoclax and hypomethylating agents-a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group.
Topics: Allografts; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Combined Modality Therapy; Decitabine; DNA Methylation; Drug Evaluation; Febrile Neutropenia; Germany; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Leukocyte Count; Myelodysplastic Syndromes; Recurrence; Retrospective Studies; Salvage Therapy; Sulfonamides; Thrombocytopenia; Transplantation Conditioning; Tumor Lysis Syndrome | 2021 |
Azacitidine and Venetoclax in AML.
Topics: Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Myeloid, Acute; Sulfonamides | 2020 |
Azacitidine and Venetoclax in AML.
Topics: Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Myeloid, Acute; Sulfonamides | 2020 |
Azacitidine and Venetoclax in AML.
Topics: Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Myeloid, Acute; Sulfonamides | 2020 |
Azacitidine and Venetoclax in AML. Reply.
Topics: Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Myeloid, Acute; Sulfonamides | 2020 |
Venetoclax + hypomethylating agents combined with dose-adjusted HAG for relapsed/refractory acute myeloid leukemia: Two case reports.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Decitabine; Drug Combinations; Fatal Outcome; Granulocyte Colony-Stimulating Factor; Homoharringtonine; Humans; Leukemia, Myeloid, Acute; Male; Neoplasm Recurrence, Local; Sulfonamides; Young Adult | 2020 |
The propriety of upgrading responses to venetoclax + azacitidine in newly diagnosed patients with acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Myeloid, Acute; Sulfonamides | 2021 |
Venetoclax and azacitidine (VenAZA) combination therapy in young unfit patients with AML: a perspective from a developing country.
Topics: Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Developing Countries; Humans; Leukemia, Myeloid, Acute; Sulfonamides | 2021 |
Azacitidine and venetoclax for the treatment of accelerated and blast phase myeloproliferative neoplasms and chronic myelomonocytic leukemia: a case series.
Topics: Azacitidine; Blast Crisis; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Myelomonocytic, Chronic; Sulfonamides | 2021 |
Cost-effectiveness of azacitidine and venetoclax in unfit patients with previously untreated acute myeloid leukemia.
Topics: Aged; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Cost-Benefit Analysis; Humans; Leukemia, Myeloid, Acute; Sulfonamides | 2021 |
Hypomethylating agents and venetoclax in acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials as Topic; Decitabine; DNA Methylation; DNA, Neoplasm; Humans; Leukemia, Myeloid, Acute; Recurrence; Salvage Therapy; Sulfonamides; Treatment Outcome | 2021 |
Venetoclax with azacitidine or decitabine in blast-phase myeloproliferative neoplasm: A multicenter series of 32 consecutive cases.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Blast Crisis; Bridged Bicyclo Compounds, Heterocyclic; Decitabine; Female; Humans; Male; Middle Aged; Myeloproliferative Disorders; Retrospective Studies; Sulfonamides; Survival Analysis; Treatment Outcome | 2021 |
Pevonedistat and azacitidine upregulate NOXA (PMAIP1) to increase sensitivity to venetoclax in preclinical models of acute myeloid leukemia.
Topics: Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Cyclopentanes; Humans; Leukemia, Myeloid, Acute; Pyrimidines; Sulfonamides | 2022 |
Daratumumab-based therapy after prior Azacytidine-Venetoclax in an octagenerian female with BPDCN (blastic plasmacytoid dendritic cell neoplasm) - a new perspective.
Topics: Antibodies, Monoclonal; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Dendritic Cells; Female; Hematologic Neoplasms; Humans; Skin Neoplasms; Sulfonamides | 2021 |
Azacitidine and venetoclax for post-transplant relapse in a case of CBFA2T3/GLIS2 childhood acute myeloid leukaemia.
Topics: Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Child; Humans; Kruppel-Like Transcription Factors; Leukemia, Myeloid, Acute; Neoplasm Recurrence, Local; Repressor Proteins; Sulfonamides | 2021 |
Venetoclax combined with azacitidine as an effective and safe salvage regimen for relapsed or refractory T-cell acute lymphoblastic leukemia: a case series.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Myeloid, Acute; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Salvage Therapy; Sulfonamides; T-Lymphocytes | 2021 |
Are myelodysplastic syndromes ready for venetoclax? Exploring future potential and considerations.
Topics: Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Sulfonamides | 2021 |
Prognostic impact of conventional cytogenetics in acute myeloid leukemia treated with venetoclax and decitabine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Cytogenetic Analysis; Decitabine; Humans; Leukemia, Myeloid, Acute; Prognosis; Sulfonamides | 2021 |
ASXL1 mutations are associated with distinct epigenomic alterations that lead to sensitivity to venetoclax and azacytidine.
Topics: Antineoplastic Agents; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Epigenesis, Genetic; Gene Expression Regulation, Leukemic; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Point Mutation; Repressor Proteins; Sulfonamides | 2021 |
Venetoclax plus azacitidine and donor lymphocyte infusion in treating acute myeloid leukemia patients who relapse after allogeneic hematopoietic stem cell transplantation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Lymphocyte Transfusion; Male; Middle Aged; Neoplasm Recurrence, Local; Sulfonamides; Transplantation, Homologous; Treatment Outcome; Young Adult | 2022 |
Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Female; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Retrospective Studies; Sulfonamides; Young Adult | 2021 |
Allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first complete remission after 5-azacitidine and venetoclax: a multicenter retrospective study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Retrospective Studies; Sulfonamides; Transplantation Conditioning; Transplantation, Homologous | 2022 |
Venetoclax and azacitidine followed by allogeneic transplant results in excellent outcomes and may improve outcomes versus maintenance therapy among newly diagnosed AML patients older than 60.
Topics: Allografts; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Myeloid, Acute; Retrospective Studies; Sulfonamides | 2022 |
Exciting times ahead for older patients with acute myeloid leukemia: azacitidine and venetoclax followed by allogeneic hematopoietic cell transplantation.
Topics: Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Sulfonamides | 2022 |
Molecular determinants of therapy response of venetoclax-based combinations in acute myeloid leukemia.
Topics: Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Myeloid, Acute; Remission Induction; Sulfonamides | 2021 |
RUNX1 mutations correlate with response to venetoclax combination therapies in relapsed/refractory acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bone Marrow Transplantation; Bridged Bicyclo Compounds, Heterocyclic; Combined Modality Therapy; Core Binding Factor Alpha 2 Subunit; Decitabine; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Prognosis; Retrospective Studies; Sulfonamides; Survival Rate | 2021 |
Limited benefit in patients with MDS receiving venetoclax and azacitidine as a bridge to allogeneic stem cell transplantation.
Topics: Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Sulfonamides | 2022 |
[Efficacy and safety of venetoclax and azacitidine in the treatment of refractory and relapsed acute myeloid leukemia].
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Myeloid, Acute; Sulfonamides | 2021 |
Whom should we treat with novel agents? Specific indications for specific and challenging populations.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials as Topic; Female; Humans; Leukemia, Myeloid, Acute; Male; Prognosis; Sulfonamides | 2021 |
Impact of Venetoclax and Azacitidine in Treatment-Naïve Patients with Acute Myeloid Leukemia and IDH1/2 Mutations.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Dancing; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Mutation; Sulfonamides | 2022 |
Impact of FLT3 Mutation on Outcomes after Venetoclax and Azacitidine for Patients with Treatment-Naïve Acute Myeloid Leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Dancing; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Sulfonamides | 2022 |
Mitochondrial inhibitors circumvent adaptive resistance to venetoclax and cytarabine combination therapy in acute myeloid leukemia.
Topics: Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Humans; Leukemia, Myeloid, Acute; Sulfonamides | 2021 |
Acute monocytic leukemia with histiocytic morphology in hematological remission after azacytidine and venetoclax therapy.
Topics: Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Child; Humans; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Sulfonamides | 2022 |
Venetoclax in combination with hypomethylating agents in previously untreated patients with acute myeloid leukemia ineligible for intensive treatment: a real-life multicenter experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Decitabine; Humans; Leukemia, Myeloid, Acute; Retrospective Studies; Sulfonamides | 2022 |
Durable response of therapy-related MDS/AML with concomitant Waldenström's macroglobulinemia treated with venetoclax and azacitidine.
Topics: Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Myeloid, Acute; Sulfonamides; Waldenstrom Macroglobulinemia | 2022 |
Achievement of rapid complete remission in an 87-year-old female patient with azacytidine-venetoclax for blastic plasmacytoid dendritic cell neoplasm.
Topics: Aged, 80 and over; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Dendritic Cells; Female; Humans; Myeloproliferative Disorders; Skin Neoplasms; Sulfonamides | 2022 |
Real-world experience with venetoclax and hypomethylating agents in myelodysplastic syndromes with excess blasts.
Topics: Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Humans; Myelodysplastic Syndromes; Sulfonamides | 2022 |
The Clinical Tumor Lysis Syndrome in a Patient with Mixed Phenotype Acute Leukemia Undergoing Induction with Venetoclax and Azacitidine: A Case Report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Myeloid, Acute; Phenotype; Sulfonamides; Tumor Lysis Syndrome | 2022 |
Central nervous system relapse of acute promyelocytic leukemia treated by oral Venetoclax with Azacitidine achieved complete remission.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Central Nervous System; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Recurrence; Remission Induction; Sulfonamides | 2022 |
Ex vivo drug sensitivity profiling-guided treatment of a relapsed pediatric mixed-phenotype acute leukemia with venetoclax and azacitidine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia; Leukemia, Myeloid, Acute; Phenotype; Sulfonamides | 2022 |
Outcomes of second allogeneic stem cell transplantation and anti-relapse strategies in patients with relapsed/refractory acute myeloid leukemia: A unicentric retrospective analysis.
Topics: Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Recurrence; Retrospective Studies; Sulfonamides | 2022 |
[Durable molecular remission in a patient with relapsed NPM1/IDH1 mutant acute myeloid leukemia treated with venetoclax combined with azacitidine: a case report].
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Nuclear Proteins; Sulfonamides | 2022 |
Shall We Dance: Evolving Partnerships of Targeted Therapies for AML.
Topics: Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Dancing; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Mutation; Sulfonamides | 2022 |
Tumor lysis syndrome and infectious complications during treatment with venetoclax combined with azacitidine or decitabine in patients with acute myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Decitabine; Febrile Neutropenia; Humans; Leukemia, Myeloid, Acute; Retrospective Studies; Sulfonamides; Tumor Lysis Syndrome | 2022 |
Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemia.
Topics: Aged; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Prospective Studies; Quality of Life; Retrospective Studies; Sulfonamides | 2022 |
A real-world study of infectious complications of venetoclax combined with decitabine or azacitidine in adult acute myeloid leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Decitabine; Humans; Leukemia, Myeloid, Acute; Retrospective Studies; Sulfonamides; Treatment Outcome | 2022 |
Outcomes and hospitalization patterns of patients with acute myelogenous leukemia treated with frontline CPX-351 or HMA/venetoclax.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Daunorubicin; Hospitalization; Humans; Leukemia, Myeloid, Acute; Sulfonamides | 2022 |
Venetoclax synergizes with gilteritinib in FLT3 wild-type high-risk acute myeloid leukemia by suppressing MCL-1.
Topics: Azacitidine; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Myeloid Cell Leukemia Sequence 1 Protein | 2022 |
Time spent at home among older adults with acute myeloid leukemia receiving azacitidine- or venetoclax-based regimens.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Myeloid, Acute; Prospective Studies | 2023 |
Outcomes Are Similar After Allogeneic Hematopoietic Stem Cell Transplant for Newly Diagnosed Acute Myeloid Leukemia Patients who Received Venetoclax + Azacitidine Versus Intensive Chemotherapy.
Topics: Adult; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Disease-Free Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Neoplasm, Residual; Recurrence; Retrospective Studies; Sulfonamides | 2022 |
Outcomes in Patients with Poor-Risk Cytogenetics with or without TP53 Mutations Treated with Venetoclax and Azacitidine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials, Phase I as Topic; Clinical Trials, Phase III as Topic; Cytogenetic Analysis; Humans; Leukemia, Myeloid, Acute; Mutation; Treatment Outcome; Tumor Suppressor Protein p53 | 2022 |
Use of CYP3Ai and impact on outcomes in patients with acute myeloid leukemia treated with venetoclax plus azacitidine in the VIALE-A study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Myeloid, Acute; Sulfonamides | 2022 |
Postremission cytopenia management in patients with acute myeloid leukemia treated with venetoclax and azacitidine in VIALE-A.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Myeloid, Acute; Sulfonamides | 2022 |
An early glimpse at azacitidine plus venetoclax for myelodysplastic syndromes.
Topics: Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Sulfonamides | 2022 |
Palbociclib promotes the antitumor activity of Venetoclax plus Azacitidine against acute myeloid leukemia.
Topics: Animals; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Leukemia, Myeloid, Acute; Mice; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyridines; Sulfonamides | 2022 |
Successful combination treatment with azacitidine and venetoclax for a patient with acute myeloid leukemia undergoing hemodialysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Myeloid, Acute; Renal Dialysis | 2022 |
SARS-CoV-2 Infection in Patients Treated with Azacitidine and Venetoclax for Acute Leukemia: A Report of a Case Series Treated in a Single Institution.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; COVID-19; Female; Humans; Leukemia, Myeloid, Acute; Male; Pandemics; SARS-CoV-2 | 2023 |
Machine Learning-Based Exploratory Clinical Decision Support for Newly Diagnosed Patients With Acute Myeloid Leukemia Treated With 7 + 3 Type Chemotherapy or Venetoclax/Azacitidine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Decision Support Systems, Clinical; Humans; Leukemia, Myeloid, Acute; Machine Learning; Sulfonamides; Treatment Outcome | 2022 |
TP53 or Not TP53: That Is the Question.
Topics: Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Cytogenetic Analysis; Humans; Leukemia, Myeloid, Acute; Mutation; Tumor Suppressor Protein p53 | 2022 |
Diagnostic challenge in mixed phenotype acute leukemia with T/megakaryocyte or T/myeloid lineages accompanied by t(3;3).
Topics: Acute Disease; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Cell Lineage; Female; Humans; Immunophenotyping; Leukemia, Myeloid, Acute; Megakaryocytes; Phenotype; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Sulfonamides | 2022 |
Utility of therapeutic drug monitoring of venetoclax in acute myeloid leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Cytochrome P-450 CYP3A Inhibitors; Drug Monitoring; Humans; Itraconazole; Leukemia, Myeloid, Acute; Sulfonamides | 2022 |
Venetoclax in Combination with Azacitidine for the Treatment of Newly Diagnosed Acute Myeloid Leukemia: A Canadian Cost-Utility Analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Canada; Cost-Benefit Analysis; Humans; Leukemia, Myeloid, Acute | 2022 |
Venetoclax and hypomethylating agent therapy in myelodysplastic syndromes: Big picture perspective.
Topics: Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Humans; Myelodysplastic Syndromes; Sulfonamides | 2023 |
Preclinical efficacy of azacitidine and venetoclax for infant KMT2A-rearranged acute lymphoblastic leukemia reveals a new therapeutic strategy.
Topics: Azacitidine; Decitabine; Humans; Infant; Leukemia, Myeloid, Acute; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Proto-Oncogene Proteins c-bcl-2 | 2023 |
Successful Haploidentical Hematopoietic Stem Cell Transplantation with Azacitidine and Venetoclax Maintenance Therapy for Acute Myeloid Leukemia with
Topics: Azacitidine; Gene Fusion; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Nuclear Pore Complex Proteins | 2023 |
Retrospective, real-life study of venetoclax plus azacitidine or low-dose cytarabine in French patients with acute myeloid leukemia ineligible for intensive chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Humans; Leukemia, Myeloid, Acute; Retrospective Studies | 2023 |
15-days duration of venetoclax combined with azacitidine in the treatment of relapsed/refractory high-risk myelodysplastic syndromes: A retrospective single-center study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Retrospective Studies | 2023 |
Venetoclax with decitabine versus decitabine monotherapy in elderly acute myeloid leukemia: a propensity score-matched analysis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Decitabine; Humans; Leukemia, Myeloid, Acute; Propensity Score; Treatment Outcome | 2022 |
Radical surgery and venetoclax plus azacitidine in an octogenarian with acute myeloid leukemia.
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Myeloid, Acute; Octogenarians | 2023 |
A retrospective assessment of real-world experience with venetoclax and azacitidine therapy in elderly acute myeloid leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Female; Humans; Leukemia, Myeloid, Acute; Male; Neutropenia; Retrospective Studies | 2023 |
Shorter duration of venetoclax administration to 14 days has same efficacy and better safety profile in treatment of acute myeloid leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Myeloid, Acute; Retrospective Studies | 2023 |
Prospective multicenter study on infectious complications and clinical outcome of 230 unfit acute myeloid leukemia patients receiving first-line therapy with hypomethylating agents alone or in combination with Venetoclax.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Myeloid, Acute; Prospective Studies | 2023 |
[Venetoclax and azacitidine induced cytogenetic response in an elderly patient with IDH2- and DNMT3A-mutated refractory acute myeloid leukemia].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Cytogenetic Analysis; Humans; Leukemia, Myeloid, Acute; Male | 2022 |
Venetoclax plus azacitidine compared with intensive chemotherapy as induction for patients with acute myeloid leukemia: retrospective analysis of an electronic medical record database in the United States.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Electronic Health Records; Humans; Leukemia, Myeloid, Acute; Retrospective Studies; United States | 2023 |
Venetoclax in combination with hypomethylating agent for the treatment of advanced myeloproliferative neoplasms and acute myeloid leukemia with extramedullary disease.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Myeloid, Acute; Myeloproliferative Disorders; Retrospective Studies; Sulfonamides | 2023 |
Tyrosine kinase inhibitors combined with venetoclax and azacytidine as an effective therapy for de novo lymphoid blast phase-chronic myeloid leukemia.
Topics: Azacitidine; Blast Crisis; Bridged Bicyclo Compounds, Heterocyclic; Fusion Proteins, bcr-abl; Humans; Protein Kinase Inhibitors; Tyrosine Kinase Inhibitors | 2023 |
High susceptibility of febrile neutropenia in Japanese patients receiving venetoclax plus azacitidine therapy for acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; East Asian People; Febrile Neutropenia; Humans; Leukemia, Myeloid, Acute | 2023 |
Report of four acute myeloid leukemia patients with sustained complete remission with less frequent administration of decitabine and venetoclax.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Decitabine; Humans; Leukemia, Myeloid, Acute; Remission Induction | 2023 |
Combination of a New Oral Demethylating Agent, OR2100, and Venetoclax for Treatment of Acute Myeloid Leukemia.
Topics: Aged; Animals; Antineoplastic Agents; Azacitidine; Humans; Leukemia, Myeloid, Acute; Mice; Quality of Life | 2023 |
Outcome of patients with acute myeloid leukemia following failure of frontline venetoclax plus hypomethylating agent therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Myeloid, Acute; Sulfonamides | 2023 |
Novel agents and regimens in acute myeloid leukemia: latest updates from 2022 ASH Annual Meeting.
Topics: Azacitidine; Congresses as Topic; Humans; Leukemia, Myeloid, Acute | 2023 |
Combinatorial BCL2 Family Expression in Acute Myeloid Leukemia Stem Cells Predicts Clinical Response to Azacitidine/Venetoclax.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Myeloid, Acute; Proteomics; Proto-Oncogene Proteins c-bcl-2; Stem Cells | 2023 |
Characterization of a multidisciplinary team's role in hospital discharge for patients receiving hypomethylating agents with venetoclax as induction therapy for acute myeloid leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Decitabine; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Patient Care Team; Patient Discharge; Treatment Outcome; Tumor Lysis Syndrome | 2023 |
Real-world treatment patterns of venetoclax and azacytidine therapy in Japanese patients with acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; East Asian People; Humans; Leukemia, Myeloid, Acute | 2023 |
Venetoclax plus azacitidine and LDAC induced high response rates in acute myeloid leukaemia in routine clinical practice.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Myeloid, Acute; Sulfonamides | 2023 |
Successful Bridging to Allogeneic Hematopoietic Stem Cell Transplantation by Azacitidine and Venetoclax in a Case of Acute Myeloid Leukemia With t(3;3)(q21.3;q26.2) Developed Early After Orthotopic Heart Transplantation.
Topics: Azacitidine; Female; Heart Transplantation; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Transplantation, Homologous | 2023 |
Clinical responses in pediatric patients with relapsed/refractory leukemia treated with azacitidine and venetoclax.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Child; Humans; Leukemia; Leukemia, Myeloid, Acute; Sulfonamides | 2023 |
Venetoclax and Azacitidine in Chinese patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy.
Topics: Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; East Asian People; Humans; Leukemia, Myeloid, Acute; Sulfonamides | 2023 |
Combination of azacitidine, venetoclax and ruxolitinib in blast phase myeloproliferative neoplasms.
Topics: Aged; Aged, 80 and over; Azacitidine; Blast Crisis; Humans; Myeloproliferative Disorders; Quality of Life; Treatment Outcome | 2023 |
Alternating venetoclax/azacytidine and FLT3 inhibitor treatment for NPM1- and FLT3-mutated acute myeloid leukemia.
Topics: Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Nuclear Proteins; Prognosis | 2023 |
Acute Myeloid Leukemia with NPM1 Mutation and Disseminated Leukemia Cutis: Achievement of Molecular Complete Remission by Venetoclax/Azacitidine Combination in a Very Old Patient.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Humans; Leukemia, Myeloid, Acute; Mutation; Nuclear Proteins | 2023 |
Venetoclax and Azacitidine Treatment in Relapsed Acute Myeloid Leukemia after Hematopoietic Stem Cell Transplantation: A Cohort Study in the Real-World Setting of a Tertiary Center
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cohort Studies; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute | 2023 |
Venetoclax and azacitidine therapy in acute myeloid leukemia patients with severe renal impairment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Myeloid, Acute; Sulfonamides | 2023 |
The ribosomal protein S6 kinase alpha-1 (RPS6KA1) induces resistance to venetoclax/azacitidine in acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Drug Resistance, Neoplasm; Humans; Leukemia, Myeloid, Acute; Ribosomal Protein S6 Kinases; Ribosomal Protein S6 Kinases, 90-kDa; RNA, Guide, CRISPR-Cas Systems | 2023 |
Case report: Positive response to venetoclax and azacitidine in the treatment of acute myeloid leukemia with myelodysplasia-related changes and blasts of the mixed T/myeloid phenotype.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Phenotype | 2023 |
[Prompt cytogenetic response by venetoclax plus azacitidine regimen in a patient with AML harboring double-minute chromosomes with MYC gene amplification].
Topics: Aged, 80 and over; Azacitidine; Chromosome Aberrations; Chromosomes; Female; Gene Amplification; Humans; In Situ Hybridization, Fluorescence; Leukemia, Myeloid, Acute | 2023 |
Acquired resistance to venetoclax plus azacitidine in acute myeloid leukemia: In vitro models and mechanisms.
Topics: Azacitidine; bcl-2-Associated X Protein; Bridged Bicyclo Compounds, Heterocyclic; Fatty Acids; Humans; Leukemia, Myeloid, Acute; Myeloid Cell Leukemia Sequence 1 Protein | 2023 |
Abbreviated venetoclax with decitabine or azacitidine in acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Decitabine; Humans; Leukemia, Myeloid, Acute | 2023 |
FUS-ERG induces late-onset azacitidine resistance in acute myeloid leukaemia cells.
Topics: Azacitidine; Chromatin; Myeloid Cell Leukemia Sequence 1 Protein | 2023 |
Venetoclax Combined with Azacytidine Can Be a First-line Treatment Option for Elderly Blastic Plasmacytoid Dendritic Cell Neoplasm.
Topics: Aged; Aged, 80 and over; Azacitidine; Dendritic Cells; Humans; Male; Myeloproliferative Disorders; Neutropenia; Skin Neoplasms | 2023 |
Clinical Correlates of Venetoclax-Based Combination Sensitivities to Augment Acute Myeloid Leukemia Therapy.
Topics: Antineoplastic Agents; Azacitidine; Humans; Leukemia, Myeloid, Acute; Proto-Oncogene Proteins c-bcl-2 | 2023 |
Venetoclax-based therapy in treatment-naïve and relapsed/refractory acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Myeloid, Acute; Retrospective Studies | 2023 |
[How did the survival of acute myeloid leukemia change over the last ten years in our unit?]
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Myeloid, Acute; Retrospective Studies | 2023 |